An infallible hand-held probe to aid cancer surgery
Canadian researchers have invented an intraoperative probe that reliably detects multiple types of tumour cells听
Patients with common widespread forms of cancer will enjoy longer life expectancy and reduced risk of recurrence thanks to a multimodal optical spectroscopy probe developed by Canadian researchers.听
In 2015, scientists at Polytechnique Montr茅al, the University of Montreal Hospital Research Center听(CRCHUM), the Montreal Neurological Institute and Hospital (The Neuro), 平特五不中, and the MUHC developed a hand-held Raman spectroscopy probe allowing surgeons to accurately detect virtually all brain cancer cells in real time during surgery.听
The research team has now perfected the invention and designed a new device with improved accuracy, sensitivity and specificity, capable of detecting not only brain cancer cells but colon, lung and skin cancer cells as well. In intraoperative testing, the multimodal optical spectroscopy probe detected cancer cells infallibly, with nearly 100 per cent sensitivity鈥攊n other words, when pointed at a cancerous region, the probe is never wrong.
This breakthrough, details of which were in the American Association for Cancer Research journal Cancer Research, is the outcome of collaborative efforts between engineer Fr茅d茅ric听Leblond and neurosurgical oncology specialist Dr.听Kevin听Petrecca.
鈥淢inimizing, or completely eliminating, the number of cancer cells during surgery is a critical part of cancer treatment, yet detecting cancer cells during surgery is challenging,鈥� explains Dr.听Petrecca, who is Chief of Neurosurgery, a brain cancer researcher, and holder of the William听Feindel Chair in Neuro-Oncology at the Neuro. 鈥淥ften it is impossible to visually distinguish cancer from normal brain, so invasive brain cancer cells frequently remain after surgery, leading to cancer recurrence and a worse prognosis. Surgically minimizing the number of cancer cells improves patient outcomes.鈥澨�
Dr. Fr茅d茅ric Leblond, Professor of Engineering Physics at Polytechnique Montr茅al and a research fellow at the University of Montreal Hospital Research Centre听(CRCHUM), notes: 鈥淭he probe we鈥檝e designed enables detection of nearly 100听per cent of cancer cells in the brain. This is a very important advance. We鈥檝e also been able to demonstrate the effectiveness of our technology in treating other forms of cancer. This means that more patients will benefit from better diagnosis, more effective treatment, and lower risk of recurrence.鈥�
The major advantage of this system is that surgeons can use it during a procedure to detect cancer cells in real time鈥攁 determination that is difficult to make via naked-eye observation.听
鈥淎 technology with extremely high accuracy is necessary, since surgeons will be using this information to help determine if tissues contain cancer cells or not. An important feature of this device is its broad applicability. We found that it effectively detects multiple cancer types, including brain, lung, colon, and skin cancers,鈥� Dr.听Petrecca concludes.
Probe combines multiple technology modalities
The intraoperative probe developed in the laboratories uses the same Raman spectroscopy technology as the researchers鈥� first-generation probe to interpret the chemical composition of the tissue examined. First developed in听2015 and tested on more than 80听patients during surgery, the probe has now been perfected by its inventors. The new version is multimodal, also using intrinsic fluorescence spectroscopy to interpret the metabolic composition of the cells, as well as diffuse reflectance spectroscopy to analyze intrinsic tissue absorption in patients.听
During recent testing on 15听other brain surgery patients, sequential use of these high-sensitivity spectroscopy techniques鈥攊ntegrated into a single sensor coupled with a detection system, in combination with stimulating lasers, a highly sensitive camera, and a spectrometer鈥攖he surgeon benefited from molecular imaging that provided never-before-seen accuracy, with cancer detection sensitivity improved by about 10听per cent compared with the first-generation probe.
Clinical trial under way
The first-generation Raman spectroscopy probe is currently the subject of a randomized controlled trial involving patients with gliomas. The study will be the first in the world to demonstrate the clinical benefits of intraoperative probe use during brain surgery. The results will be used to establish the protocol for an upcoming clinical trial of the second-generation multimodal probe.
In 2015, Dr.听Petrecca and Professor Leblond created a company, ODS Medical, to commercialize the probe. They have since initiated the formal approval process with the U.S. Food and Drug Administration听(FDA), to ensure transfer of the technology to hospital settings within a few听years.
About the study
The article reporting on the study, 鈥淗ighly accurate detection of cancer in situ with intraoperative, label-free, multimodal optical spectroscopy,鈥� was published in the American Association for Cancer Research journal Cancer Research on June听28,听2017. The work was supported by the Fonds de recherche du Qu茅bec鈥揘ature et technologies, the Natural Sciences and Engineering Research Council of Canada, Collaborative Health Research Projects (CIHR and NSERC), the Groupe de recherche en sciences et technologies biom茅dicales, and National Bank of Canada. The authors are Michael听Jermyn, Jeanne听Mercier, Kelly听Aubertin, Joannie听Desroches, Kirk听Urmey, Jason听Karamchandiani, Eric听Marple, Marie-Christine听Guiot, Frederic听Leblond, and Kevin听Petrecca.
The original press release, with photos and video, can be viewed at:
